Current and Future Burden of Chronic Nonmalignant Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2031-2041

  Udompap, Prowpanga ^a   Kim, Donghee ^a   Kim, W Ray ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Burden; Chronic Liver Disease; Health Economics

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; TENOFOVIR DISOPROXIL;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOIMMUNE LIVER DISEASE; CHOLESTATIC LIVER DISEASE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; END STAGE LIVER DISEASE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEMOCHROMATOSIS; HIGH RISK BEHAVIOR; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; TREATMENT INDICATION; UNITED STATES; WILSON DISEASE; CHRONIC DISEASE; COST OF ILLNESS; INCIDENCE; LIVER DISEASES; SURVIVAL ANALYSIS;

CHRONIC DISEASE; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; INCIDENCE; LIVER DISEASES; PREVALENCE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84944415081     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.08.015     Document Type: Review

References (97)

1. Schuppan D., Afdhal N.H. Liver cirrhosis. Lancet 2008, 371:838-851.
2. Scaglione S., Kliethermes S., Cao G., et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015, 49:690-696.
3. Murphy SL, Kochanek KD. Deaths: final data for 2010. Updated May 8, 2013. Centers for Disease Control and Prevention website. Available at:. Accessed June 2015. http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf.
4. Murray C.J., Atkinson C., Bhalla K., et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013, 310:591-608.
5. Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385:117-171. GBD 2013 Mortality and Causes of Death Collaborators.
6. Centers for Disease Control and Prevention. Deaths: final data for 2013. Available at:. Accessed June, 2015. http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_02.pdf.
7. Suryaprasad A., Byrd K.K., Redd J.T., et al. Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009. Am J Public Health 2014, 104(Suppl 3):S350-S358.
8. Kim W.R., Brown R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
9. Kim W.R. Epidemiology of hepatitis B in the United States. Hepatology 2009, 49(Suppl):S28-S34.
10. Kim W.R., Smith J.M., Skeans M.A., et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant 2014, 14(Suppl 1):69-96.
11. Averhoff F.M., Glass N., Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012, 55(Suppl 1):S10-S15.
12. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010, 107:14757-14762.
13. Ly K.N., Xing J., Klevens R.M., et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156:271-278.
14. Razavi H., Elkhoury A.C., Elbasha E., et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013, 57:2164-2170.
15. Kanwal F., Hoang T., Kramer J.R., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011, 140:1182-1188 e1.
16. Gordon S.C., Pockros P.J., Terrault N.A., et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatol 2012, 56:1651-1660.
17. El Khoury A.C., Klimack W.K., Wallace C., et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012, 19:153-160.
18. Davis G.L., Albright J.E., Cook S.F., et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338.
19. Hatzakis A., Chulanov V., Gadano A.C., et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm: volume 2. J Viral Hepat 2015, 22(Suppl 1):26-45.
20. Kabiri M., Jazwinski A.B., Roberts M.S., et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014, 161:170-180.
21. Soriano V., Labarga P., Fernandez-Montero J.V., et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral Res 2013, 97:36-40.
22. Thursz M., Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014, 11:28-35.
23. Lemoine M., Nayagam S., Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 2013, 8:371-380.
24. Singal A.K., Kuo Y.F., Anand B.S. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol 2012, 24:1178-1184.
25. Singal A.K., Jampana S.C. Current management of alcoholic liver disease. Curr Drug Abuse Rev 2014, 7:18-28.
26. World Health Organization. Global status report on alcohol and health. Geneva, Switzerland. 2011. Available at: 2011. Accessed June 18, 2015. http://www.who.int/substance:abuse/publications/global_alcohol_report/msbgsruprofiles.pdf.
27. Substance Abuse and Mental Health Services Administration. 2013 National Survey on Drug Use and Health (NSDUH): table 2.46B-alcohol use, binge alcohol use, and heavy alcohol use in the past month among persons aged 18 or older, by demographic characteristics: percentages, 2012 and 2013. 2013. Available at: 2013. Accessed June 18, 2015. http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf.
28. Paula H., Asrani S.K., Boetticher N.C., et al. Alcoholic liver disease-related mortality in the United States: 1980-2003. Am J Gastroenterol 2010, 105:1782-1787.
29. Saka B.S. Recent trends in the epidemiology of alcoholic liver disease. Clin Liver Dis 2013, 2:53-56.
30. Ahmed S., Ali R., Qadir M., et al. Asthma in children: management issues for family doctors. Oman Medical Journal 2010, 25:253-255.
31. Rehm J., Samokhvalov A.V., Shield K.D. Global burden of alcoholic liver diseases. J Hepatol 2013, 59:160-168.
32. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
33. Ruhl C.E., Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124:71-79.
34. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
35. Speliotes E.K., Massaro J.M., Hoffmann U., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51:1979-1987.
36. Kim D., Kim W.R., Kim H.J., et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013, 57:1357-1365.
37. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
38. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
39. Khashab M.A., Liangpunsakul S., Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008, 10:73-80.
40. Ahmed M.H., Abu E.O., Byrne C.D. Non-alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities?. Prim Care Diabetes 2010, 4:129-137.
41. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010, 103:71-83.
42. Ruhl C.E., Everhart J.E. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015, 41:65-76.
43. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
44. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
45. Angulo P., Bugianesi E., Bjornsson E.S., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013, 145:782-789 e4.
46. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
47. Calori G., Lattuada G., Ragogna F., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011, 54:145-152.
48. Jepsen P., Vilstrup H., Mellemkjaer L., et al. Prognosis of patients with a diagnosis of fatty liver: a registry-based cohort study. Hepatogastroenterology 2003, 50:2101-2104.
49. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49:608-612.
50. Soderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
51. Ekstedt M., Hagstrom H., Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015, 61:1547-1554.
52. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
53. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
54. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38:420-427.
55. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
56. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
57. Wong R.J., Cheung R., Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014, 59:2188-2195.
58. Wong R.J., Aguilar M., Cheung R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015, 148:547-555.
59. Baumeister S.E., Volzke H., Marschall P., et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008, 134:85-94.
60. Younossi Z.M., Zheng L., Stepanova M., et al. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol 2015, 49:222-227.
61. Ott J.J., Stevens G.A., Groeger J., et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30:2212-2219.
62. Seeff L.B., Beebe G.W., Hoofnagle J.H., et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987, 316:965-970.
63. Kowdley K.V., Wang C.C., Welch S., et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012, 56:422-433.
64. Mitchell T., Armstrong G.L., Hu D.J., et al. The increasing burden of imported chronic hepatitis B: United States, 1974-2008. PLoS One 2011, 6:e27717.
65. Buti M., Oyaguez I., Lozano V., et al. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. PharmacoEconomics 2013, 31:63-75.
66. Buti M., Brosa M., Casado M.A., et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009, 51:640-646.
67. Bacon B.R., Adams P.C., Kowdley K.V., et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:328-343.
68. Powell L.W., Dixon J.L., Ramm G.A., et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006, 166:294-301.
69. Distante S., Robson K.J., Graham-Campbell J., et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004, 115:269-279.
70. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008, 358:221-230.
71. Dar F.S., Faraj W., Zaman M.B., et al. Outcome of liver transplantation in hereditary hemochromatosis. Transpl Int 2009, 22:717-724.
72. EASL clinical practice guidelines: Wilson's disease. J Hepatol 2012, 56:671-685. European Association for Study of the Liver.
73. Roberts E.A., Schilsky M.L. American Association for Study of Liver Disease. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008, 47:2089-2111.
74. Bellary S., Hassanein T., Van Thiel D.H. Liver transplantation for Wilson's disease. J Hepatol 1995, 23:373-381.
75. Arnon R., Annunziato R., Schilsky M., et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011, 25:E52-E60.
76. Arnon R., Kerkar N., Davis M.K., et al. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant 2010, 14:796-805.
77. Colp C., Pappas J., Moran D., et al. Variants of alpha 1-antitrypsin in Puerto Rican children with asthma. Chest 1993, 103:812-815.
78. Silverman E.K., Miletich J.P., Pierce J.A., et al. Alpha-1-antitrypsin deficiency: high prevalence in the St Louis area determined by direct population screening. Am Rev Respir Dis 1989, 140:961-966.
79. O'Brien M.L., Buist N.R., Murphey W.H. Neonatal screening for alpha1-antitrypsin deficiency. J Pediatr 1978, 92:1006-1010.
80. de Serres F.J., Blanco I., Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet 2003, 64:382-397.
81. Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand 1988, 77:847-851.
82. Fairbanks K.D., Tavill A.S. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008, 103:2136-2141. quiz 42.
83. Kemmer N., Kaiser T., Zacharias V., et al. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008, 40:1492-1494.
84. Carey E.J., Iyer V.N., Nelson D.R., et al. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis. Liver Transpl 2013, 19:1370-1376.
85. Deneau M., Jensen M.K., Holmen J., et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013, 58:1392-1400.
86. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
87. Hurlburt K.J., McMahon B.J., Deubner H., et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002, 97:2402-2407.
88. Ngu J.H., Bechly K., Chapman B.A., et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J Gastroenterol Hepatol 2010, 25:1681-1686.
89. Myers R.P., Shaheen A.A., Fong A., et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009, 50:1884-1892.
90. Kim W.R., Lindor K.D., Locke G.R., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
91. Inoue K., Hirohara J., Nakano T., et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995, 15:70-77.
92. Watson R.G., Angus P.W., Dewar M., et al. Low prevalence of primary biliary cirrhosis in Victoria, Australia: Melbourne Liver Group. Gut 1995, 36:927-930.
93. Ilyas J.A., O'Mahony C.A., Vierling J.M. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011, 25:765-782.
94. Kuiper E.M., Hansen B.E., Metselaar H.J., et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010, 10:144.
95. Molodecky N.A., Kareemi H., Parab R., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011, 53:1590-1599.
96. Toy E., Balasubramanian S., Selmi C., et al. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol 2011, 11:83.
97. Eaton J.E., Talwalkar J.A., Lazaridis K.N., et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013, 145:521-536.